Ultragenyx Pharmaceutical (NASDAQ:RARE) Announces Earnings Results, Misses Estimates By $0.06 EPS

Ultragenyx Pharmaceutical (NASDAQ:RARE) released its earnings results on Tuesday. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing the consensus estimate of ($1.10) by ($0.06), FiscalAI reports. The business had revenue of $173.00 million during the quarter, compared to the consensus estimate of $182.49 million. During the same period in the prior year, the company posted ($1.81) earnings per share. Ultragenyx Pharmaceutical’s quarterly revenue was up 8.2% compared to the same quarter last year.

Here are the key takeaways from Ultragenyx Pharmaceutical’s conference call:

• GENGLYCOS and FAYUVI received FDA approval and have begun launching, with strong early demand, 35 qualified treatment centers active, and the company on track to exceed 40 by year-end.
• Ultragenyx reaffirmed its 2026 revenue guidance of $730 million–$760 million and expects to achieve full-year GAAP profitability and positive operating cash flow in 2027, supported by revenue growth and substantial cost reductions.
• The company expects 2027 R&D expense below $350 million and SG&A below $375 million after reducing headcount by approximately 20%; it also secured roughly $350 million in net, non-dilutive proceeds from selling two priority review vouchers.
• Disappointing phase III results led Ultragenyx to discontinue GTX-102 for Angelman syndrome, while UX701 for Wilson disease was terminated after failing to produce a sufficient biochemical response in most patients, contributing to significant workforce reductions.
• Management remains encouraged by setrusumab activity in osteogenesis imperfecta and is discussing potential regulatory paths with the FDA, but has not yet determined whether another prospective trial will be required.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE traded down $1.23 during midday trading on Thursday, reaching $15.94. The stock had a trading volume of 3,101,286 shares, compared to its average volume of 2,873,491. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -3.07 and a beta of 0.37. The company’s fifty day simple moving average is $16.45 and its two-hundred day simple moving average is $22.78. Ultragenyx Pharmaceutical has a 1-year low of $12.73 and a 1-year high of $39.89.

More Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx reported FDA approvals for GENGLYCOS and FAYUVI and agreed to sell two Priority Review Vouchers for a combined $413 million. It also reaffirmed its 2027 profitability outlook and expects R&D expenses in 2027 to be at least 50% below 2025 levels. Third-quarter results and guidance
• Neutral Sentiment: Analyst views were mixed: Canaccord maintained a Buy despite cutting its target to $34; TD Cowen raised its target to $19, and Morgan Stanley raised its target to $22 while retaining Equal Weight. Goldman Sachs and Wedbush lowered their targets to $17 and $22, respectively, with Neutral ratings. Analyst insights
• Negative Sentiment: Third-quarter revenue of $173 million missed analyst expectations of about $182.5 million, and the $1.16-per-share loss was wider than the roughly $1.10 loss expected. Revenue grew 8.2% year over year and the loss narrowed from a year earlier, but the shortfall may weigh on sentiment. Q3 earnings coverage
• Negative Sentiment: A critical investor assessment points to dependence on CRYSVITA, limited contributions from newer launches, and pipeline setbacks. It argues that the path toward profitability relies heavily on deep R&D cuts rather than strong revenue growth. Assessment of Ultragenyx’s outlook

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Bank of America lowered Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating in a research report on Thursday, September 3rd. Canaccord Genuity Group decreased their target price on Ultragenyx Pharmaceutical from $39.00 to $34.00 and set a “buy” rating for the company in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, October 6th. Jefferies Financial Group lowered their target price on Ultragenyx Pharmaceutical from $77.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, September 3rd. Finally, Robert W. Baird downgraded Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $40.00 to $16.00 in a report on Thursday, September 3rd. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $30.47.

Insider Activity at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,066 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $15.27, for a total value of $107,897.82. Following the transaction, the chief financial officer owned 89,229 shares of the company’s stock, valued at $1,362,526.83. This represents a 7.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 8,510 shares of company stock worth $127,561 in the last three months. Insiders own 5.20% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.